Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000690168 | SCV000817847 | uncertain significance | Developmental and epileptic encephalopathy, 25 | 2022-10-31 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 251 of the SLC13A5 protein (p.Ala251Val). This variant is present in population databases (rs150517372, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with SLC13A5-related conditions. ClinVar contains an entry for this variant (Variation ID: 569521). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SLC13A5 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001785702 | SCV002027726 | uncertain significance | not provided | 2024-05-22 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV000690168 | SCV002055668 | uncertain significance | Developmental and epileptic encephalopathy, 25 | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003163143 | SCV003871204 | uncertain significance | Inborn genetic diseases | 2023-01-20 | criteria provided, single submitter | clinical testing | The c.752C>T (p.A251V) alteration is located in exon 6 (coding exon 6) of the SLC13A5 gene. This alteration results from a C to T substitution at nucleotide position 752, causing the alanine (A) at amino acid position 251 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |